JMP Securities Reiterates Market Outperform on TELA Bio, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst David Turkaly has reiterated a 'Market Outperform' rating on TELA Bio (NASDAQ:TELA), maintaining a price target of $15.
March 22, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst David Turkaly reiterates a 'Market Outperform' rating on TELA Bio, with a maintained price target of $15.
The reiteration of a 'Market Outperform' rating and the maintenance of a $15 price target by a reputable analyst like David Turkaly could signal confidence in TELA Bio's future performance. This endorsement may positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100